📈 Stock
At the end of Jan 2026, Mike Exton ran the Nasdaq Closing Bell to celebrate Lexicon Pharmaceuticals' 30th anniversary.
A recent positive end-of-Phase 2 meeting with the FDA now positions pilavapadin to advance into Phase 3 trials.
Mike Exton, CEO, Lexicon Pharmaceuticals | JPM 2026
A clear message to investors: get in!
Related
Brad Sitko, CIO, XOMA Royalty | Onyx Live | JPM 2026
The biotech industry destroys billions in shareholder value every year - failed trials, depleted cash, and abandoned pipelines leaving investors with nothing.
Avi Veidman, CEO, Nucleai | Onyx Live | JPM 2026
90% of oncology drugs fail in clinical trials - costing billions and, more importantly, delaying life-saving treatments for patients who need them now.
Will biotech still be relevant in 2030? | Treehill Partners Ep. 3 | JPM 2026
Will large pharma's AI adoption and deployment to drug development redefine biotech's role and business model?
Paul Denslow, CEO, Intus Bio | Onyx Live | JPM 2026
38 trillion bacteria live in your gut — yet most microbiome tests can only identify them at the genus level, missing the strains that actually matter.